Sphera Funds Management’s Teva Pharmaceuticals TEVA Stock Holding History

Sphera Funds Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,268,900	Closed	-$53.1M	–	138
2024 Q2	$53.1M	Buy	3,268,900 +136,200	+4%	+$2.1M	7.24%	1
2024 Q1	$44.2M	Buy	3,132,700 +1,848,700	+144%	+$23.3M	6.21%	1
2023 Q4	$13.4M	Sell	1,284,000 -3,729,800	-74%	-$34.8M	2.16%	10
2023 Q3	$51.1M	Sell	5,013,800 -3,130,900	-38%	-$29.2M	9.32%	1
2023 Q2	$61.3M	Buy	8,144,700 +6,107,700	+300%	+$49.5M	9.58%	1
2023 Q1	$18M	Sell	2,037,000 -185,300	-8%	-$1.83M	3.01%	8
2022 Q4	$20.3M	Buy	2,222,300 +12,300	+0.6%	+$107K	4.35%	5
2022 Q3	$17.8M	Sell	2,210,000 -1,171,600	-35%	-$10.4M	2.48%	11
2022 Q2	$25.4M	Buy	3,381,600 +1,491,600	+79%	+$13M	2.72%	11
2022 Q1	$17.7M	Buy	+1,890,000	New	+$15.8M	2.51%	13
2021 Q4	–	Sell	-1,050,000	Closed	-$10.2M	–	123
2021 Q3	$10.2M	Sell	1,050,000 -860,000	-45%	-$8.05M	0.86%	39
2021 Q2	$18.9M	Buy	1,910,000 +1,021,200	+115%	+$10.8M	1.28%	18
2021 Q1	$10.3M	Buy	+888,800	New	+$10.2M	0.79%	26
2020 Q1	–	Sell	-1,220,600	Closed	-$12M	–	97
2019 Q4	$12M	Sell	1,220,600 -329,400	-21%	-$2.94M	0.99%	17
2019 Q3	$10.7M	Sell	1,550,000 -500,000	-24%	-$3.83M	1.65%	13
2019 Q2	$18.9M	Buy	+2,050,000	New	+$24.7M	2.59%	12
2017 Q2	–	Sell	-1,500	Closed	-$4.74M	–	138
2017 Q1	$4.74M	Sell	1,500 -213,500	-99%	-$7.29M	0.93%	25
2016 Q4	$7.79M	Buy	+215,000	New	+$8.58M	1.97%	12
2015 Q3	–	Sell	-6,500	Closed	-$38.4M	–	139
2015 Q2	$38.4M	Buy	6,500 +3,000	+86%	+$185K	3.76%	4
2015 Q1	$21.8M	Sell	3,500 -460,700	-99%	-$26.8M	2.27%	9
2014 Q4	$1.8M	Buy	464,200 +89,000	+24%	+$4.96M	0.31%	94
2014 Q3	$20.2M	Buy	375,200 +371,990	+11,588%	+$19.7M	2.49%	14
2014 Q2	$1.24M	Buy	3,210 +210	+7%	+$10.7K	0.31%	72
2014 Q1	$2.53M	Sell	3,000 -97,000	-97%	-$4.48M	0.58%	34
2013 Q4	$4.01M	Buy	+100,000	New	+$3.94M	1.12%	20

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's TEVA Position: Q1 2026 in Review

Sphera Funds Management increased its Teva Pharmaceuticals (TEVA) stake by 1.2% in Q1 2026, buying an estimated $433K and bringing the position to 1,136,975 shares worth $34.2M. The position accounts for 5.44% of the portfolio, ranked #2.

Sphera Funds Management first reported a position in TEVA in Q4 2013 and has held it in 45 quarters since. The position peaked at $51.5M in Q4 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Sphera Funds Management held 1,136,975 shares of Teva Pharmaceuticals worth $34.2M as of Q1 2026.
Sphera Funds Management bought 13,450 Teva Pharmaceuticals shares in Q1 2026, an estimated $433K.
Teva Pharmaceuticals made up 5.44% of Sphera Funds Management's portfolio in Q1 2026, its #2 holding.
Sphera Funds Management first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 45 quarters since.
Sphera Funds Management's Teva Pharmaceuticals position peaked at $51.5M in Q4 2015.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.